



ISEC HEALTHCARE LTD.
(Company Registration No. 201400185H)
(Incorporated in the Republic of Singapore)
NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the Annual General Meeting (“AGM”) of ISEC HEALTHCARE LTD. will be convened and held by electronic means on Thursday, 20 April 2023 at 10.00 a.m. to transact the following business:

ORDINARY BUSINESS

- To receive and adopt the Directors’ Statement and the Audited Financial Statements for the financial year ended 31 December 2022 together with the Independent Auditor’s Report thereon. **(Resolution 1)**
- To declare a final tax exempt (one-tier) dividend of 1.08 Singapore cents per ordinary share for the financial year ended 31 December 2022 (FY2021: Final tax exempt (one-tier) dividend of 0.30 Singapore cents per ordinary share). **(Resolution 2)**
[See Explanatory Note (i)]
- To re-elect the following Directors of the Company retiring pursuant to Article 114 of the Constitution of the Company, and who have, being eligible, offered themselves for re-election as Directors:
Mr Chen Bang **(Resolution 3)**
Mr Li Li **(Resolution 4)**
[See Explanatory Note (ii)]
- To approve the payment of Directors’ fees amounting to S\$120,000 for the financial year ending 31 December 2023, payable quarterly in arrears. (FY2022: S\$120,000). **(Resolution 5)**
- To re-appoint Mazars LLP as the Independent Auditors of the Company for the ensuing year and to authorise the Directors of the Company to fix their remuneration. **(Resolution 6)**
- To transact any other ordinary business which may properly be transacted at an Annual General Meeting.

AS SPECIAL BUSINESS

To consider and if thought fit, to pass the following resolutions as Ordinary Resolutions, with or without any modifications:

7. Authority to allot and issue shares

That pursuant to Section 161 of the Companies Act 1967 (the “Companies Act”) and Rule 806 of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst (the “Catalist Rules”), the Directors of the Company be authorised and empowered to:

- allot and issue shares in the capital of the Company (“Shares”) whether by way of rights, bonus or otherwise; and/or
- make or grant offers, agreements or options (collectively, “Instruments”) that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares, at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and
- (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force, provided that:

(1) the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) to be issued pursuant to this Resolution shall not exceed one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments made or granted pursuant to this Resolution) to be issued other than on a pro rata basis to shareholders of the Company shall not exceed fifty per centum (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);

(2) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time of the passing of this Resolution, after adjusting for:

- new Shares arising from the conversion or exercise of any convertible securities;
- new Shares arising from the exercising of share options or vesting of share awards; and
- any subsequent bonus issue, consolidation or subdivision of shares;

and, in sub-paragraph (1) above and this sub-paragraph (2), “subsidiary holdings” has the meaning given to it in the Catalist Rules; Adjustments in accordance with sub-paragraph (2)(a) or (2)(b) are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution.

- in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), the Companies Act and the Constitution, for the time being, of the Company; and
- unless revoked or varied by the Company in a general meeting, such authority shall continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (iii)] **(Resolution 7)**

8. Authority to issue Shares under the ISEC Healthcare Share Option Scheme (the “Share Option Scheme”)

That pursuant to Section 161 of the Companies Act, the Directors of the Company be authorised to offer and grant options in accordance with the provisions of the Share Option Scheme and to allot and issue from time to time such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the exercise of options under the Share Option Scheme, provided always that the aggregate number of new Shares to be allotted and issued pursuant to the Share Option Scheme, when added to the aggregate number of Shares issued and issuable in respect of all options granted under the Share Option Scheme and any other share option, share incentive, performance share or restricted share plan implemented by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company on the day preceding the date of grant of the option, as determined in accordance with the provisions of the Share Option Scheme. Such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (iv)] **(Resolution 8)**

9. Authority to issue Shares under the ISEC Healthcare Performance Share Plan (the “Performance Share Plan”)

That pursuant to Section 161 of the Companies Act, the Directors of the Company be authorised and empowered to grant awards in accordance with the provisions of the Performance Share Plan and to allot and issue from time to time, such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the Performance Share Plan, provided always that the aggregate number of Shares issued and issuable in respect of all awards granted under the Performance Share Plan, when added to all Shares issued and issuable in respect of the ISEC Healthcare Share Option Scheme and any other share scheme implemented by the Company for the time being in force, shall not exceed fifteen per centum (15%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company on the day preceding the date of grant of the award. Such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (v)] **(Resolution 9)**

10. Proposed Renewal of the Share Buyback Mandate

That
(a) for the purposes of Sections 76C and 76E of the Companies Act, the Directors of the Company be and are hereby authorised to exercise all the powers of the Company to purchase or otherwise acquire Shares not exceeding in aggregate the Prescribed Limit (as hereinafter defined), at such price(s) as may be determined by the Directors of the Company from time to time up to the Maximum Price (as hereinafter defined), whether by way of:

- market purchases transacted on Catalist through the ready market, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose of the share buyback (“Market Purchases”); and/or
- off-market purchases effected pursuant to an equal access scheme as defined in Section 76C of the Companies Act (“Off-Market Purchase”), and otherwise in accordance with all other laws and regulations, including but not limited to, the Company’s Constitution, the provisions of the Companies Act and the Catalist Rules as may for the time being be applicable (the “Share Buyback Mandate”);

(b) any Share that is purchased or otherwise acquired by the Company pursuant to the Share Buyback Mandate shall, at the discretion of the Directors of the Company, either be cancelled or held in treasury and dealt with in accordance with the Companies Act;

(c) unless varied or revoked by the Company in general meeting, the authority conferred on the Directors of the Company pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the passing of this Resolution and expiring on the earlier of:

- the date on which the next AGM of the Company is held or is required by law to be held;
- the date on which the purchases or acquisitions of the shares pursuant to the Share Buyback Mandate is carried out to the full extent mandated; or
- the date on which the authority conferred in the Share Buyback Mandate is varied or revoked by the shareholders in a general meeting, whichever is the earliest (“Relevant Period”).

(d) for purposes of this Resolution:

“Prescribed Limit” means 10% of the total number of issued ordinary shares of the Company (“Shares”) as at the date of passing of this Resolution unless the Company has, at any time during the Relevant Period, effected a reduction of the share capital of the Company in accordance with the applicable provisions of the Companies Act, in which event the total number of Shares shall be taken to be the total number of Shares as altered (excluding any treasury shares and subsidiary holdings that may be held by the Company from time to time); and “Maximum Price” in relation to a Share to be purchased, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) not exceeding:

- in the case of a Market Purchase, 105% of the Average Closing Price; and
- in the case of an Off-Market Purchase pursuant to an equal access scheme, 120% of the Average Closing Price, where:
- “Average Closing Price” means the average of the closing market prices of a Share over the last five market days, on which transactions in the Shares were recorded, before the day on which the purchase or acquisition of Shares was made, or as the case may be, the day of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs during the relevant five (5)-day period and the day on which the purchases are made;
- “day of the making of the offer” means the day on which the Company announces its intention to make an offer for an Off-Market Purchase, stating the purchase price (which shall not be more than the Maximum Price) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and
- “market day” means a day on which the SGX-ST is open for trading in securities.

(e) any of the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including without limitation, to execute all such documents as may be required and to approve any amendments, alterations or modifications to any documents), as they or he may consider desirable, expedient or necessary to give effect to the transactions contemplated by this Resolution.
[See Explanatory Note (vi)] **(Resolution 10)**

By Order of the Board

Ngiam May Ling
Company Secretary
Singapore
5 April 2023

Explanatory Notes:

- For the financial year ended 31 December 2021, the Company paid a final tax exempt (one-tier) dividend of 0.30 Singapore cents per ordinary share. For the financial year ended 31 December 2022, the Company paid a first interim tax exempt (one-tier) dividend of 0.48 Singapore cents per ordinary share and will be paying a final tax exempt (one-tier) dividend of 1.08 Singapore cents per ordinary share, if approved by the members at this AGM.
- Resolutions 3 and 4 are for the re-election of Mr Chen Bang and Mr Li Li, Directors of the Company who retire by rotation at this AGM. Mr Chen Bang and Mr Li Li, will upon re-election as Directors of the Company, remain as Non-Executive Directors and will be considered non-independent. For more information on Mr Chen Bang and Mr Li Li, please refer to the “Board of Directors” section in this Annual Report 2022.
- The Ordinary Resolution 7, if passed, will empower the Directors of the Company, effective until the conclusion of the next annual general meeting of the Company, or the date by which the next annual general meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to allot and issue Shares, make or grant Instruments convertible into Shares and to issue Shares pursuant to such Instruments, up to a number not exceeding, in total, one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company, of which up to fifty per centum (50%) may be issued other than on a pro-rata basis to shareholders.

For determining the aggregate number of Shares that may be issued, the percentage of issued Shares (excluding treasury shares and subsidiary holdings) will be calculated based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time Ordinary Resolution 7 is passed after adjusting for new Shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards and any subsequent bonus issue, consolidation or subdivision of shares. These adjustments are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution.

(iv) The Ordinary Resolution 8, if passed, will empower the Directors of the Company to issue Shares up to an amount in aggregate not exceeding fifteen per centum (15%) of the issued share capital (excluding treasury shares and subsidiary holdings) of the Company pursuant to the Share Option Scheme, and such other share-based incentive scheme or share plan, on the date preceding the date of the relevant grant. This authority is in addition to the general authority to issue Shares sought under Ordinary Resolution 7.

(v) The Ordinary Resolution 9, if passed, will empower the Directors of the Company, effective until the conclusion of the next annual general meeting of the Company, or the date by which the next annual general meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to grant awards under the Performance Share Plan in accordance with the provisions of the Performance Share Plan and to allot and issue from time to time such number of fully-paid Shares as may be required to be issued pursuant to the vesting of the awards under the Performance Share Plan subject to the maximum number of Shares prescribed under the terms and conditions of the Performance Share Plan.

The aggregate number of Shares which may be allotted and issued pursuant to the Performance Share Plan and under any other share incentive scheme or share plan adopted by the Company for the time being in force, is limited to fifteen per centum (15%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company on the day preceding the date of grant of the option and/or award. This authority is in addition to the general authority to issue Shares sought under Ordinary Resolution 7.

(vi) The Ordinary Resolution 10, if passed, will empower the Directors of the Company, effective period commencing from the date on which the ordinary resolution in relation to the proposed renewal of the Share Buyback Mandate is passed in a general meeting and expiring on the earliest of the date on which the next Annual General Meeting is held or is required by law to be held, the date the said mandate is revoked or varied by the Company in a general meeting, or the date on which the purchases of shares pursuant to the Share Buyback Mandate are carried out to the full extent mandated, to repurchase ordinary shares of the Company by way of market purchases or off-market purchases of up to ten per cent (10%) of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the Maximum Price as defined in this Notice of Annual General Meeting.

The rationale for, the authority and limitation on, the sources of funds to be used for the purchase or acquisition including the amount of financing and the financial effects of the purchase or acquisition of ordinary shares by the Company pursuant to the Share Buyback Mandate on the audited consolidated financial statements of the Group for the financial year ended 31 December 2022 are set out in greater detail in the Appendix to the Annual Report 2022.

Important Notes:

1. No attendance at the AGM

The AGM is being convened, and will be held, by electronic means pursuant to the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts, Unit Trusts and Debenture Holders) Order 2020. Printed copies of this Notice of AGM, Proxy Form and the Annual Report 2022 will not be sent to Shareholders. Instead, the Notice of AGM, the Proxy Form and the Annual Report 2022 may be accessed at the Company’s website at the URL <https://www.isechhealthcare.com>, and will also be made available on SGXNet at the URL <https://www.sgx.com/securities/company-announcements>. Members will not be able to attend in person.

Alternative arrangements have been put in place to allow Shareholders to participate at the AGM by:

- observing and/or listening to the AGM proceedings via “live” audio-and-visual webcast via their mobile phones, tablets or computers or “live” audio-only stream via telephone (Live Webcast);
- submitting questions in advance of the AGM or during the AGM via an online text box; and/or
- voting at the AGM (i) “live” by the Shareholders themselves via electronic means or (ii) by appointing the Chairman of the Meeting or proxy(ies) (other than the Chairman of the Meeting) as proxy to attend and vote on their behalf at the AGM.

Details of the steps for pre-registration, submission of questions and voting at the AGM are set out in detail below.

2. Pre-Registration to attend the AGM remotely

Shareholders (including SRS investors) and, where applicable, appointed proxy(ies), who wish to vote “live” at the AGM must pre-register at the pre-registration website at <https://go.lumiengage.com/ISECAGM2023>; from now till 10.00 am on 18 April 2023 to enable the Company to verify their status as Shareholders. If they wish to appoint the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting) to vote on their behalf, they should submit a Proxy Form/approach their respective SRS Operators in accordance with paragraph (5) below. Following the verification, authenticated persons will receive a confirmation email which will contain the instructions to access the “live” audio-and-visual webcast and a telephone number to access the “live” audio-only stream of the AGM proceedings, via the e-mail address provided during pre-registration. Persons who do not receive the confirmation email by 12.00 pm on 19 April 2023, but have registered by 10.00 am on 18 April 2023 deadline should contact the Company’s Share Registrar, Boardroom Corporate & Advisory Services Pte Ltd, by telephone at 6536 5355 during Monday to Friday, from 8.30 a.m. to 5.30 p.m. or by email to ISECAGM2023@boardroomlimited.com.

Deadline to pre-register: By 10.00 am on 18 April 2023

Investors holding Shares through relevant intermediaries (other than SRS investors) who wish to participate in the “live” broadcast of the AGM should contact the relevant intermediary through which they hold such Shares as soon as possible, no later than 10.00 am on 10 April 2023 (being 7 working days before the date of the AGM) in order to make the necessary arrangements for them to participate in the AGM.

3. Submission of questions

Shareholders and SRS investors will be able to ask questions at the AGM by typing in and submitting their questions through the online text box function via the audio-visual webcast platform. It is important for Shareholders and SRS investors to have their web-browser devices ready for asking questions during the Live Webcast.

Shareholders and SRS investors who pre-registered and are verified in accordance with paragraph (2) above are also encouraged to submit questions related to the proposed resolutions to be tabled for approval at the AGM in the following manner:

- via the pre-registration website at <https://go.lumiengage.com/ISECAGM2023>;
- by email to isec.agm@gmail.com;
- if submitted by post, be deposited at the registered office of the Company at 51 Goldhill Plaza #10-07/08 Singapore 308900; or
- during the AGM via an online text box.

Shareholders will need to identify themselves when posing questions by providing the following details:

- the Shareholder’s full name as it appears on the CDP/SRS share records;
- the Shareholder’s NRIC/Passport/UEN number;
- the Shareholder’s contact number and email address; and
- the manner in which the Shareholder holds his/her/its shares in the Company (e.g. via SRS).

Please note that the Company will not be able to answer questions from persons who provide insufficient details to enable the Company to verify his/her/its shareholder status.

Shareholders are strongly encouraged to submit their questions electronically via email.

Deadline to submit questions: By 10.00 a.m. on 13 April 2023

The Company will endeavour to respond to substantial and relevant questions received from Shareholders relating to the agenda of the AGM and publish its responses on SGXNet and the Company’s website prior to the AGM. The Company will also address any subsequent clarifications sought, or follow-up questions, prior to, or at, the AGM in respect of substantial and relevant matters.

The Company will adopt real-time electronic communication facilities i.e. an online text box for the Shareholders to raise questions during the AGM and receive responses to these substantial and relevant questions from the Company prior to vote casting.

The Company will, within one (1) month after the date of the AGM, publish the minutes of the AGM on Company’s website and on SGXNet, and the minutes will include the responses to substantial and relevant questions referred to above.

4. Voting at the AGM

Shareholders and SRS investors who wish to attend and vote electronically (in real time) at the AGM must pre-register at the pre-registration website in accordance with paragraph (2) above. “Live” voting will be conducted during the AGM for Shareholders and SRS investors attending the Live Webcast (and not the audio-only feed via telephone). It is important for Shareholders and SRS investors to have their web-browser devices ready for voting during the Live Webcast.

5. Voting by the appointment of Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting)

A member (whether individual or corporate) who does not wish to attend and vote (in real time) at the AGM may submit a Proxy Form to appoint the Chairman of the Meeting as his/her/its proxy or proxy(ies) (other than the Chairman of the Meeting) to attend and vote on his/her/its behalf at the AGM if such member wishes to exercise his/her/its voting rights at the AGM.

Where a member (whether individual or corporate) appoints the Chairman of the Meeting as his/her/its proxy or proxy(ies) (other than the Chairman of the Meeting), if no specific instructions as to voting, or abstentions from voting, in respect of a resolution is given in the Proxy Form, the Chairman of the Meeting or proxy(ies) (other than the Chairman of the Meeting) will vote or abstain from voting at his/her discretion.

SRS investors who wish to appoint the Chairman of the Meeting as proxy should approach their respective SRS Operators to submit their votes at least seven (7) working days before the AGM (i.e. by 10.00 a.m. on 10 April 2023) in order to allow sufficient time for their respective relevant intermediaries to in turn submit a Proxy Form to appoint the Chairman of the Meeting to vote on their behalf by the cut-off date.

For the avoidance of doubt, pre-registration is not required if a shareholder only intends to appoint the Chairman of the Meeting as his/her/its proxy or proxy(ies) (other than the Chairman of the Meeting) and does not intend to attend the AGM. The Chairman of the Meeting as proxy or proxy(ies) appointed (other than the Chairman of the Meeting), need not be a Member of the Company.

The instrument appointing the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting), which can be assessed at the SGXNet at the URL <https://www.sgx.com/securities/company-announcements> and the Company’s website at the URL <http://www.isechhealthcare.com>, must be submitted to the Company in the following manner:

- if electronically, be submitted via email at isec.agm@gmail.com; or
- if by post, be deposited at the office of the Company’s Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632;

in either case, by no later than 10.00 a.m. on 18 April 2023, being forty-eight (48) hours before the time fixed for the holding of the AGM and in default the instrument of proxy shall be treated as invalid. Shareholders who wish to submit an instrument of proxy must first download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

Deadline to submit Proxy Form: By 10.00 a.m. on 18 April 2023

Where an instrument appointing the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting), submitted by email, it must be authorised in the following manner, failing which the instrument may be treated as invalid:

- by way of the affixation of an electronic signature by the appointor or his/her duly authorised attorney or, as the case may be, an officer or duly authorised attorney of a corporation; or
- by way of the appointor or his/her duly authorised attorney or, as the case may be, an officer or duly authorised attorney of a corporation signing the instrument under hand and submitting a scanned copy of the signed instrument by email.

A corporation which is a Shareholder may by resolution of its directors or other governing body authorise such person as it thinks fit to act as its representative at the AGM and the person so authorised shall upon production of a copy of such resolution certified by a director of the corporation to be a true copy, be entitled to exercise the powers on behalf of the corporation so represented as the corporation could exercise in person if it were an individual.

The Company shall be entitled to reject the instrument appointing the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting) if it is incomplete, improperly completed or illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting) (including any related attachment). In addition, in the case of a member whose Shares are entered in the Depository Register, the Company may reject any instrument appointing the Chairman of the Meeting as proxy or proxy(ies) (other than the Chairman of the Meeting) if the member, being the appointor, is not shown to have Shares entered against his name in the Depository Register as at seventy-two (72) hours before the time appointed for holding the AGM, as certified by The Central Depository (Pte) Limited to the Company.

6. Completion and return of the instrument appointing the Chairman of the AGM or proxy(ies) (other than the Chairman of the Meeting) will not prevent a shareholder from attending and voting (in real time) via electronic means at the AGM if he/she/it subsequently wishes to do so, provided that in the event of such attendance by the shareholder via electronic means, the relevant instrument submitted by the shareholder shall be deemed to be revoked.

7. All documents and information relating to the business of the Meeting (including this Notice of Meeting and the instrument appointing a proxy) have been published on the SGXNet at the URL <https://www.sgx.com/securities/company-announcements> and the Company’s website at the URL <http://www.isechhealthcare.com>.

Personal Data Privacy:

By submitting personal data to the Company (or its agents) or an instrument appointing the Chairman of the AGM or proxy(ies) (other than the Chairman of the Meeting) to attend, speak and vote at the AGM and/or any adjournment thereof, a member of the Company consents to the collection, use and disclosure of the member’s personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of the appointment of the Chairman of the AGM as proxy or proxy(ies) (other than the Chairman of the Meeting) for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any Applicable Laws, listing rules, regulations and/or guidelines, and recording and transmitting images and voice recordings when broadcasting the proceedings of the AGM through a live audio-visual webcast or live audio-only stream.